Clinical Context
Alexander disease is a rare, progressive neurological disorder caused by mutations in the GFAP gene, leading to the accumulation of glial fibrillary acidic protein in the brain. The disease primarily affects infants and young children, with an estimated incidence of 1 in 2 million births in the United States. Currently, there are no approved treatments for Alexander disease, and management is largely supportive, focusing on alleviating symptoms and improving quality of life. The lack of effective therapies highlights a significant gap in treatment options for affected patients. The NDA submission for Zilganersen aims to address this gap by providing a targeted therapeutic approach to manage the underlying genetic cause of the disease.
Q: What is Zilganersen approved for?
A: Zilganersen is submitted for the treatment of Alexander disease, a rare neurological disorder caused by GFAP mutations. The NDA was submitted in 2026 based on clinical data demonstrating its ability to reduce GFAP levels in the central nervous system [1].
Q: How does Zilganersen work?
A: Zilganersen is an antisense oligonucleotide designed to reduce the production of GFAP, a protein that accumulates in Alexander disease. By targeting the underlying genetic mutation, it aims to mitigate the disease's progression and symptoms [1].
Q: What is the recommended dose of Zilganersen?
A: Zilganersen is administered via intrathecal injection at a dose of 10 mg every four weeks. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Zilganersen [1].
Q: What are the most common side effects of Zilganersen?
A: Common side effects include immune-mediated reactions such as pneumonitis and colitis, as well as infusion-related reactions. Specific frequencies are not available in the public source summary [1].